Vertex Pharmaceuticals INC / Ma Form 4 insider transactions

Ourania Tatsis, EVP, Chief Reg. & Quality Off. of Vertex Pharmaceuticals Inc / Ma, received 8,251 shares of common stock on July 21, 2026.

Amit Sachdev, EVP Chief Patient & Ext Af Off of Vertex Pharmaceuticals Inc / Ma, received 8,251 shares of common stock on July 21, 2026.

Bruce I Sachs, a Director of Vertex Pharmaceuticals Inc / Ma, received 100 shares of common stock on July 15, 2026.

Alan M Garber, a Director of Vertex Pharmaceuticals Inc / Ma, received 32 shares of common stock on July 15, 2026.

Vertex Pharmaceuticals EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, reported a sale of 1,500 common shares for $524.99 each, executed under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP, Chief Commercial Officer Duncan McKechnie reported a sale of 1,541 shares of common stock on July 2, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals EVP and Chief Legal Officer Joy Liu reports a transaction involving common stock under a pre-arranged trading plan.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, executed a sale of common stock under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic executed a Rule 10b5-1 trading plan transaction, selling 4,062 shares of common stock.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported transactions involving company common stock under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP and Chief Legal Officer, Joy Liu, reported a transaction involving common stock, executed under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported transactions involving company common stock under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP, Chief Scientific Officer Mark E. Bunnage reported a sale of common stock executed under a pre-arranged trading plan.

Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold 1,354 shares of common stock for $453.45 per share, totaling $613,540.30, as part of a pre-arranged trading plan.

Vertex Pharmaceuticals director Suketu Upadhyay reported the conversion of 796 restricted stock units into deferred stock units and the acquisition of 2,866 stock options.

Vertex Pharmaceuticals director Nancy Thornberry reported the acquisition of restricted stock units, stock options, and a deferral of shares into deferred stock units.

Director Jennifer Schneider reported the acquisition of restricted stock units and stock options alongside a deferral of vested shares.

Vertex Pharmaceuticals Director Bruce Sachs was granted 2,866 stock options as part of standard equity compensation.

Vertex Pharmaceuticals Director Diana McKenzie reported a routine equity grant and subsequent deferral of shares into deferred stock units.

EVP and Chief Legal Officer Joy Liu sold 1,104 shares of Vertex Pharmaceuticals common stock on May 1, 2026.

Vertex Pharmaceuticals Director Michel Lagarde was granted 2,866 fully vested stock options with an exercise price of $424.45.

Vertex Pharmaceuticals Director Alan M. Garber reports transactions involving common stock and stock options.

Vertex Pharmaceuticals Director Lloyd Carney reported a transaction involving the acquisition of 2,866 shares of common stock.

Vertex Pharmaceuticals Director Sangeeta Bhatia reported transactions involving company common stock, including the acquisition of restricted stock units and the sale of shares under a pre-arranged trading plan.

Vertex Pharmaceuticals director Suketu Upadhyay acquired 80.508 deferred stock units as part of board compensation.

Director Bruce Sachs was granted 107.345 deferred stock units as part of his compensation for service on the board.

Director Alan Garber acquired 33.898 deferred stock units of Vertex Pharmaceuticals as part of his board compensation.

Vertex Pharmaceuticals EVP and Chief Legal Officer, Joy Liu, reported a transaction involving the acquisition of common stock under a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, sold 2,329 shares of common stock for $450.95 per share as part of a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, sold 2,329 shares of common stock for $481.79 per share under a pre-arranged 10b5-1 trading plan.